• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.

    8/6/26 10:17:34 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIIB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    BIOGEN INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)




    09062X103

    (CUSIP Number)
    06/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    09062X103


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    16,623,432.57
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    18,294,523.51
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,294,523.51
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    09062X103


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    18,294,523.51
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,294,523.51
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BIOGEN INC
    (b)Address of issuer's principal executive offices:

    225 BINNEY STREET,Cambridge,MA,USA,02142
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    09062X103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    18294523.51
    (b)Percent of class:

    12.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    18294523.51

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BIOGEN INC. No one other person's interest in the COMMON STOCK of BIOGEN INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:08/05/2026
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:08/05/2026

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $BIIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB

    DatePrice TargetRatingAnalyst
    7/13/2026$235.00Hold → Buy
    Truist
    6/8/2026$255.00Hold → Buy
    Needham
    5/15/2026Outperform
    Evercore ISI
    4/22/2026$225.00Neutral → Buy
    UBS
    4/20/2026$250.00Equal Weight → Overweight
    Wells Fargo
    4/14/2026$214.00Neutral → Overweight
    Piper Sandler
    2/20/2026$185.00Equal Weight
    Barclays
    2/9/2026$194.00 → $228.00Buy
    H.C. Wainwright
    More analyst ratings

    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Minor Lloyd sold $239,750 worth of shares (1,186 units at $202.15), decreasing direct ownership by 31% to 2,689 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    8/5/26 4:03:20 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    6/11/26 5:50:34 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    6/11/26 5:47:54 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biogen upgraded by Truist with a new price target

    Truist upgraded Biogen from Hold to Buy and set a new price target of $235.00

    7/13/26 8:58:02 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen upgraded by Needham with a new price target

    Needham upgraded Biogen from Hold to Buy and set a new price target of $255.00

    6/8/26 8:21:53 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI resumed coverage on Biogen

    Evercore ISI resumed coverage of Biogen with a rating of Outperform

    5/15/26 8:16:23 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Head of Pharm Ops and Tech Murphy Nicole bought $585 worth of shares (3 units at $195.03), increasing direct ownership by 0.02% to 19,611 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:16:40 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    5/5/25 4:17:10 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/20/24 9:13:26 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZURZUVAE issued to BIOGEN INC

    Submission status for BIOGEN INC's drug ZURZUVAE (SUPPL-3) with active ingredient ZURANOLONE has changed to 'Approval' on 04/20/2026. Application Category: NDA, Application Number: 217369, Application Classification: Labeling

    4/23/26 6:14:48 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen Completes Acquisition of RayThera Inc.

    CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026. "We are excited about the potential of these immunology assets as we continue to strengthen and diversify our pipeline for long-term growth," said Priya Singhal, M.D., M.P.H., Executive Vice Pr

    8/6/26 6:15:00 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website at https://investor.stoket

    8/5/26 8:00:00 AM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

    – Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 – – Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 – – $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through to potential U.S. commercialization of zorevunersen in early 2028 – – Webcast and conference call for analy

    8/3/26 4:01:00 PM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BIIB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.

    SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)

    8/6/26 10:17:34 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Biogen Inc.

    10-Q - BIOGEN INC. (0000875045) (Filer)

    7/29/26 6:36:19 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOGEN INC. (0000875045) (Filer)

    7/29/26 6:10:24 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Leadership Updates

    Live Leadership Updates

    View All

    Biogen Appoints Michael J. Parini as Chief Legal Officer

    CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions. "Michael brings to Biogen a rare combination of deep legal and industry expertise as well as broad operational leadership that will further contribute to Biogen’s next chapter of renewed growth," said Christopher A. Viehbacher, President and Chief Executive O

    7/15/26 8:15:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

    –Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R

    7/13/26 7:30:00 AM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

    NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE:BFAM) will replace Tri Pointe Homes Inc. (NYSE:TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.Remitly Global Inc. (NASD: RELY) will replace Apellis Pharmaceuticals Inc. (NASD: APLS). S&P 500 constituent Biogen Inc. (NASD: BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.Following is a summary of the changes that will take

    5/7/26 6:01:00 PM ET
    $APLS
    $BFAM
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Consumer Discretionary

    $BIIB
    Financials

    Live finance-specific insights

    View All

    Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

    – Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 – – Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 – – $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through to potential U.S. commercialization of zorevunersen in early 2028 – – Webcast and conference call for analy

    8/3/26 4:01:00 PM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Monday, August 3, 2026, at 4:30 p.m. ET, to discuss second quarter 2026 business and financial updates. The webcast will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call

    7/27/26 4:01:00 PM ET
    $STOK
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

    Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid doses through Week 48 compared with placebo plus standard of care, supporting reduced long-term steroid exposureReduced flare rates and immune marker improvements: In other findings presented at EULAR 2026, improvements in immunological markers and reduced flare rates were observed, supporting the potential of dapirolizumab pegol to address the complex burden of SLE BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Bi

    6/4/26 1:00:00 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care